Genetic activation of glycolysis in osteoblasts preserves bone mass in type I diabetes

Cell Chem Biol. 2023 Sep 21;30(9):1053-1063.e5. doi: 10.1016/j.chembiol.2023.07.003. Epub 2023 Aug 9.

Abstract

Type I diabetes (T1D) impairs bone accrual in patients, but the mechanism is unclear. Here in a murine monogenic model for T1D, we demonstrate that diabetes suppresses bone formation resulting in a rapid loss of both cortical and trabecular bone. Single-cell RNA sequencing uncovers metabolic dysregulation in bone marrow osteogenic cells of diabetic mice. In vivo stable isotope tracing reveals impaired glycolysis in diabetic bone that is highly responsive to insulin stimulation. Remarkably, deletion of the insulin receptor reduces cortical but not trabecular bone. Increasing glucose uptake by overexpressing Glut1 in osteoblasts exacerbates bone defects in T1D mice. Conversely, activation of glycolysis by Pfkfb3 overexpression preserves both trabecular and cortical bone mass in the face of diabetes. The study identifies defective glucose metabolism in osteoblasts as a pathogenic mechanism for osteopenia in T1D, and furthermore implicates boosting osteoblast glycolysis as a potential bone anabolic therapy.

Keywords: Glut1; Pfkfb3; Type I diabetes; bone; glucose; glycolysis; hyperglycemia; hypoinsulinemia; insulin; osteoblasts.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Bone Density
  • Diabetes Mellitus, Experimental*
  • Diabetes Mellitus, Type 1* / complications
  • Diabetes Mellitus, Type 1* / genetics
  • Diabetes Mellitus, Type 1* / metabolism
  • Glycolysis
  • Humans
  • Mice
  • Osteoblasts / metabolism